Secondary Assessment Method
Title	Efficacy and survival
Number of patients screened	19
Number of patients enrolled	12
Number of patients evaluable for toxicity	12
Number of patients evaluated for efficacy	12
Evaluation method	RECIST 1.1
Response assessment, CR	1 (8.3%)
Response assessment, PR	5 (41.6%)
Response assessment, SD	5 (41.6%)
Response assessment, PD	1 (1%)
Median duration assessment, PFS	11.3 months (CI: 7.7-33.1 months)
Median duration assessment, response duration	20.6 months (13.9-31.2 months)
Median duration assessment, duration of treatment	19 months (4.4-31.2 months)
Outcome notes, efficacy	The median follow-up time was 27.6 months (range 4.4-43.5 months), and the median duration of treatment was 19 months (range 4.4-31.2 months). The ORR was 50%, with one complete response (CR) and 5 partial responses (PR). The disease control rate was 92% (n = 11/12) of the patients (Fig. 2). One patient had PD due to new osseous metastasis, though target lesions decreased in size at the same time. Radiological PFS at 6 and 12 months was reported in 67.7% and 33.5% of patients, respectively. Treatment was continued in 5 patients beyond progression (41.7%) (Fig. 3). The median PFS was 11.3 months (95% CI: 7.7-33.1 months) (Fig. 4 ).